Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Burkitt Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Biphenotypic, Acute 2Oropharyngeal Neoplasms 1Multiple Myeloma 1Lymphoma 1Hematologic Neoplasms 1Cranial Nerve Diseases 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Dexamethasone 242Lenalidomide 147daratumumab 125Bortezomib 102pomalidomide 88Calcium Dobesilate 76carfilzomib 75Cyclophosphamide 71Specimen Handling 42isatuximab 41Biopsy 40belantamab mafodotin 37fludarabine 36Magnetic Resonance Spectroscopy 35talquetamab 29Melphalan 28dexamethasone acetate 27dexamethasone 21-phosphate 27auricularum 26iberdomide 25ixazomib 22fludarabine phosphate 22selinexor 21elotuzumab 21Whole-Body Irradiation 14X-Rays 13tocilizumab 12venetoclax 11Mycophenolic Acid 10trametinib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × Medrol Veriderm × 1 year × Clear all
NCT07101445 2026-02-10

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Emory University

Phase 4 Recruiting
94 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡